Analysis of risk factors and different treatments for infections caused by carbapenem-resistant Acinetobacter baumannii in Shaanxi, China

被引:0
作者
He, Xiaoliang [1 ]
Tang, Jin [1 ]
He, Sanjun [1 ]
Huang, Xiaoxia [1 ]
机构
[1] Hanzhong Cent Hosp, Dept Clin Lab, 22 Kangfu Rd, Hanzhong, Shaanxi, Peoples R China
关键词
Molecular epidemiology; Drug resistance; Mortality; Prognosis; KLEBSIELLA-PNEUMONIAE; CLINICAL ISOLATE; MORTALITY; PREDICTORS; SULBACTAM; EVOLUTION; OUTCOMES;
D O I
10.1186/s12879-024-10036-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background The global threat of Carbapenem-resistant Acinetobacter baumannii (CRAB) has intensified as resistance to carbapenems continues to rise in recent decades. We aimed to explore risk factors, molecular epidemiology, and antimicrobial therapy of CRAB infection. Methods The clinical data of 110 patients infected with A. baumannii from December 2021 to December 2022 were retrospectively analyzed. Patients were divided into a carbapenem-resistance group (55 patients) and carbapenem-sensitive group (CSAB; 55 patients) based on resistance to carbapenem, and the risk factors of patients infected with CRAB were analyzed. Fifty-five patients with CRAB infection who received antimicrobial therapy were divided into a combination therapy group (45 patients) and a monotherapy group (10 patients), and differences between the two groups were compared. Whole-genome sequencing analysis was performed to assess resistance genes. Phylogenetic analysis was performed to explore the characteristics of CRAB isolates. Results Among the total 110 patients, the rate of poor prognosis in the CRAB group was 43.6% (24/55). Mechanical ventilation (odds ratio [OR] = 5.364, 95% confidence interval [CI] 1.462-19.679, P = 0.011) and puncture (OR = 19.935, 95% CI 1.261-315.031, P = 0.012) were independent risk factors for CRAB infection. Of 55 patients in the antimicrobial regimen study, 45 received combination therapy (including dual, triple, or quadruple antibiotic therapy) and 10 received monotherapy. Univariate analysis revealed significant differences between the combination group and monotherapy group for admission to the intensive care unit and wound infection (P < 0.05). The CRAB strains of 26 patients taking carbapenem-based combination therapy were mainly ST208, ST1968, and ST195, among which patients with ST1968 strains had higher 28-day mortality. Furthermore, the blaOXA-23 gene was harbored in ST1968, ST195, and ST208. Conclusions Mortality was significantly higher in patients infected with CRAB than with CSAB. Mechanical ventilation and puncture were independent risk factors in predicting CRAB infections. The distribution of CRAB was dominated by ST208, ST1968, and ST195, among which patients with ST1968 had higher 28-day mortality. The blaOXA-23 gene appears to be widely disseminated.
引用
收藏
页数:9
相关论文
共 50 条
[21]   Bloodstream Infections Caused by Carbapenem-Resistant Pathogens in Intensive Care Units: Risk Factors Analysis and Proposal of a Prognostic Score [J].
Montrucchio, Giorgia ;
Costamagna, Andrea ;
Pierani, Tommaso ;
Petitti, Alessandra ;
Sales, Gabriele ;
Pivetta, Emanuele ;
Corcione, Silvia ;
Curtoni, Antonio ;
Cavallo, Rossana ;
De Rosa, Francesco Giuseppe ;
Brazzi, Luca .
PATHOGENS, 2022, 11 (07)
[22]   Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019 [J].
Pogue, Jason M. ;
Zhou, Yun ;
Kanakamedala, Hemanth ;
Cai, Bin .
BMC INFECTIOUS DISEASES, 2022, 22 (01)
[23]   Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections in Wuhan, China [J].
Liu, Chan ;
Liu, Lan ;
Jin, Ming-ming ;
Hu, Yang-bo ;
Cai, Xuan ;
Wan, Lu ;
Zhang, Hai-yue ;
Li, Rui-yun ;
Wu, Xiao-jun .
CURRENT MEDICAL SCIENCE, 2022, 42 (01) :68-76
[24]   The Characterisation of Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Teaching Hospital in Malaysia [J].
Lau, Min Yi ;
Ponnampalavanar, Sasheela ;
Chong, Chun Wie ;
Dwiyanto, Jacky ;
Lee, Yee Qing ;
Woon, Jia Jie ;
Kong, Zhi Xian ;
Jasni, Azmiza Syawani ;
Lee, Michelle Chin Chin ;
Obaidellah, Unaizah Hanum ;
Teh, Cindy Shuan Ju .
ANTIBIOTICS-BASEL, 2024, 13 (11)
[25]   Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections [J].
August, Benjamin ;
Matlob, Andrew ;
Kale-Pradhan, Pramodini B. .
ANNALS OF PHARMACOTHERAPY, 2024, 58 (07) :735-741
[26]   Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study [J].
Vivo, Amanda ;
Fitzpatrick, Margaret A. ;
Suda, Katie J. ;
Jones, Makoto M. ;
Perencevich, Eli N. ;
Rubin, Michael A. ;
Ramanathan, Swetha ;
Wilson, Geneva M. ;
Evans, Martin E. ;
Evans, Charlesnika T. .
BMC INFECTIOUS DISEASES, 2022, 22 (01)
[27]   Evaluation of Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae in an Intensive Care Unit: A Retrospective Study [J].
Kerimoglu, Elif ;
Catak, Tuba ;
Kilinc, Anil .
ANTIBIOTICS-BASEL, 2025, 14 (07)
[28]   Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence [J].
Kollef, Marin ;
Dupont, Herve ;
Greenberg, David E. ;
Viale, Pierluigi ;
Echols, Roger ;
Yamano, Yoshinori ;
Nicolau, David P. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 62 (02)
[29]   Prevalence, Risk Factors, and Outcome of Carbapenem-resistant Acinetobacter Infections in a Community Hospital in Madinah, Saudi Arabia [J].
Gaifer, Zied ;
Fallatah, Raneem ;
Alanazi, Alhanouf ;
Alfagi, Raghad ;
Alharbi, Lina ;
Osman, Haitham .
SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES, 2024, 12 (04) :306-313
[30]   Global escalation in carbapenem-resistant Enterobacterales and carbapenem-resistant Acinetobacter baumannii infections: Serious threat to human health from the pink corner [J].
Sannathimmappa, Mohan .
BIOMEDICAL AND BIOTECHNOLOGY RESEARCH JOURNAL, 2023, 7 (01) :9-16